List view / Grid view
16 May 2017 | By European Federation of Pharmaceutical Industries and Associations (EFPIA)
The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news. To celebrate our success, we will be counting down…
5 January 2017 | By Niamh Marriott, Digital Editor
Amorsa has announced a research, option and license agreement with Janssen to develop and commercialise a novel small molecule drug candidate for depression...
14 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries...
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a protein believed to play a role in autoimmune rheumatoid arthritis...
In this Spectroscopy In-Depth Focus: The benefits of NIRS in monitoring and controlling a crystallisation process; Pharmaceutical applications of terahertz spectroscopy and imaging; and much more...
16 August 2016 | By Janssen
Following succesful phase II trials, the FDA have granted a Breakthrough Therapy Designation for esketamine, an investigational antidepressant medication...
21 January 2016 | By Victoria White
More than 80 companies and organisations have signed the Declaration on Combating Antimicrobial Resistance (AMR), an industry-wide call to action...
2 December 2015 | By Victoria White
Johnson & Johnson has announced four new public-private partnerships to significantly reduce the burden of HIV incidence, especially among adolescent girls...
5 November 2015 | By Victoria White
The acquisition includes Novira's portfolio of novel antivirals, including its lead candidate, NVR 3-778...
3 November 2015 | By London Business School
The Future of Healthcare - striking a balance between patients, value and innovation. Monday 7 December 2015...
22 July 2015 | By Victoria White
Stelara has progressed into Phase III development for axSpA and, following its anticipated approval, is forecast to achieve sales of $244.7 million in 2024...
9 June 2015 | By Victoria White
Johnson & Johnson and a group of leading research organisations are launching the OPTICS Project - Open Translational Science in Schizophrenia...
28 May 2015 | By Victoria White
Johnson & Johnson has accepted the 1 March 2015 binding offer from Cardinal Health to acquire its Cordis business for an approximate value of $2 billion...
7 May 2015 | By Victoria White
J&J has announced a first-of-its-kind partnership that enlists a third party to review compassionate use requests made for investigational medicines...
